logo-loader
viewInstem PLC

Instem PLC's Phil Reason says they've been really busy during lockdown and welcomes new Korea deal

Instem PLC's (LON:INS) Phil Reason speaks to Proactive London's Andrew Scott after announcing they've won a contract worth US$1mln to provide services to Biotoxtech, which runs the largest non-clinical research and development facility in South Korea. Reason adds that they've been 'really busy' during the lockdown period as the majority of their revenue comes from clients whose laboratories are regarded as "essential businesses" with many working on COVID-19 related vaccines and therapies.

Quick facts: Instem PLC

Price: 515 GBX

AIM:INS
Market: AIM
Market Cap: £105.48 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Instem PLC named herein, including the promotion by the Company of Instem PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Instem PLC has 'significant capital' to accelerate acquisition strategy...

Instem PLC's (LON:INS) Phil Reason tells Proactive London's Andrew Scott he's pleased with its first-half trading. He says the number's were in line with forecasts and momentum has continued into the second half. Revenues for the six months ended June 30, 2020, were up 20%, or 12% on a...

on 22/7/20

2 min read